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ARTICLE
GWAS in childhood acute lymphoblastic leukemia
reveals novel genetic associations at chromosomes
17q12 and 8q24.21
Joseph L. Wiemels1,2,3,4, Kyle M. Walsh1,2, Adam J. de Smith1, Catherine Metayer5, Semira Gonseth 1,4,
Helen M. Hansen2, Stephen S. Francis1,6, Juhi Ojha1, Ivan Smirnov2, Lisa Barcellos5, Xiaorong Xiao5,
Libby Morimoto5, Roberta McKean-Cowdin4, Rong Wang7, Herbert Yu 8, Josephine Hoh7,
Andrew T. DeWan7 & Xiaomei Ma7
Childhood acute lymphoblastic leukemia (ALL) (age 0–14 years) is 20% more common in
Latino Americans than non-Latino whites. We conduct a genome-wide association study in a
large sample of 3263 Californian children with ALL (including 1949 of Latino heritage) and
3506 controls matched on month and year of birth, sex, and ethnicity, and an additional
12,471 controls from the Kaiser Resource for Genetic Epidemiology Research on Aging
Cohort. Replication of the strongest genetic associations is performed in two independent
datasets from the Children’s Oncology Group and the California Childhood Leukemia Study.
Here we identify new risk loci on 17q12 near IKZF3/ZPBP2/GSDMB/ORMDL3, a locus
encompassing a transcription factor important for lymphocyte development (IKZF3), and at
an 8q24 region known for structural contacts with the MYC oncogene. These new risk loci
may impact gene expression via local (four 17q12 genes) or long-range (8q24) interactions,
affecting function of well-characterized hematopoietic and growth-regulation pathways.
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Acute lymphoblastic leukemia (ALL), the most commontype of cancer in children, has an increasingly cleargenetic etiology with a role for both rare high-penetrance
genetic predisposition alleles1 and more common low-penetrance
alleles. These latter alleles were discovered via genome-wide
association studies (GWAS), which identified genetic risk factors
at ARID5B, CEBPE, IKZF1, CDKN2A, PIP4K2A, and GATA32–5.
Additional loci were recently identified at LHPP and ELK36.
While most of these genes encode hematopoietic transcription
factors (TFs), the causal variants underlying these genetic asso-
ciations remain unclear, apart from a missense polymorphism in
CDKN2A7–9 and single-nucleotide polymorphisms (SNPs) dis-
rupting TF-binding sites in the promoters of CEBPE10 and
ARID5B11. These prior GWAS focused on non-Latino white
populations; however, the highest rate of childhood ALL globally
is found in Latinos in the United States (US)12. We sought to
identify additional risk alleles involved in the etiology of ALL in
both Latinos and non-Latinos by leveraging a large, ethnically
diverse population in California in conjunction with an array
specifically designed for the Latino population, while supple-
menting with additional accessible controls genotyped on the
same platform. We replicated our findings in two independent
childhood ALL case–control datasets from the Children’s
Oncology Group (COG) and the California Childhood Leukemia
Study (CCLS). We identify two new genetic loci impacting
childhood ALL risk, which will aid in our understanding of the
etiology of this disease.
Results
Association analysis. After quality control, 757,935 polymorphic
autosomal SNPs and 19,240 subjects (3263 cases, 15,977 controls,
which included genotyped controls run specifically for this study
and additional public controls, see Supplementary Table 1)
remained for discovery analyses. Case–control association tests
were stratified by race/ethnicity including 10,533 Latino subjects
(1949 cases, 8584 controls), 4735 non-Latino white subjects (1184
cases, 3551 controls), and 3972 African-American subjects (130
cases, 3842 controls), and then the race/ethnicity-stratified
GWAS were combined via meta-analysis. Sample size and
ancestral heterogeneity precluded the inclusion of more minor
populations (e.g., Southeast Asians, Indian subcontinental, and
other races/ethnicities) for the current analysis. Associations
reached genome-wide statistical significance (i.e., P< 5.0 × 10−8
in an additive logistic regression analysis) at known ALL risk loci,
including: ARID5B, IKZF1, PIP4K2A, and CEBPE among Latinos,
and ARID5B, IKZF1, and PIP4K2A for non-Latino whites (Sup-
plementary Table 2). No SNPs reached genome-wide significance
among African Americans, likely due to the relatively small
sample size. Analyses by each racial/ethnic subgroup did not
reveal any novel associations at genome-wide statistical
significance.
The three race/ethnicity-stratified discovery GWAS revealed
associations reaching genome-wide statistical significance (i.e., P
< 5.0 × 10−8 using a fixed-effects meta-analysis) at five known
ALL risk loci (ARID5B, IKZF1, PIP4K2A, CEBPE, and CDKN2A)
(Fig. 1 and Supplementary Table 2) and three novel loci at
chromosome 7p15.3 (rs2390536, near SP4, odds ratio (OR) =
1.20, 95% confidence interval (CI): 1.13–1.29, P = 3.6 × 10−8),
chromosome 8q24.21 (rs4617118, in a gene desert, OR = 1.27,
95% CI: 1.17–1.38, P = 3.1 × 10−9), and chromosome 17q12
(rs2290400, near the hematopoietic TF IKZF3, OR = 1.18, 95%
CI: 1.11–1.25, P = 2.1 × 10−8) (Fig. 1 and Table 1). For these novel
loci, no heterogeneity in association was noted across the three
ethnicities (heterogeneity P values were insignificant and I2 values
were low, Supplementary Table 3). In addition, a random-effects
meta-analysis applied to these data yielded similar ORs and P
values. Recently identified GWAS hits at LHPP, ELK3, and
GATA3 (rs35837782, rs4762284, and rs3824662, respectively)3,6
were not directly genotyped on the Axiom array, but when those
SNPs were imputed in our dataset, replication was achieved in a
fixed-effect meta-analysis of the three race/ethnicity-stratified
discovery GWAS (P = 5.7 × 10−6, 2.1 × 10−3, and 2.3 × 10−10,
respectively, Supplementary Table 2).
Using 1000 Genomes SNP data as a reference13, we imputed
additional SNPs within a 1Mb region centered on the three novel
SNP associations. In parallel, we used additional genome-wide
SNP array data to impute these regions in non-overlapping
European-ancestry ALL patients from the COG (N = 959 cases)
and controls from the Wellcome Trust Case–Control Consortium
(N = 2624 controls), and 530 additional Latino ALL cases and 511
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Fig. 1Manhattan plot of P values resulting from meta-analysis of three separate analyses in the California population (Latinos, non-Latino whites, and non-
Latino blacks) including study-specific controls and GERA controls (total N= 3263 cases, 15,977 controls). The locations of prior identified GWAS hits are
indicated by their gene acronyms. New genetic associations identified in this study are highlighted in bold. These association peaks exceed the Bonferroni
genome-wide P value cutoff of 5 × 10−8 indicated by a horizontal line
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02596-9
2 NATURE COMMUNICATIONS |  (2018) 9:286 |DOI: 10.1038/s41467-017-02596-9 |www.nature.com/naturecommunications
Latino controls from the CCLS (a set of cases and controls from
California distinct from our discovery set). Using these data, we
successfully replicated the novel SNP associations at 8q24 (OR =
1.30, 95% CI: 1.14–1.49, Pmeta = 1.29 × 10−4) and near IKZF3 (OR
= 1.14, 95% CI: 1.03–1.26, Pmeta = 0.013) (Table 1). For some
datasets, the top hit SNP was imputed as shown (Table 1). While
the SP4 locus did not replicate in the combined COG European
and CCLS Latinos replication datasets (Pmeta = 0.075), it was
nominally associated with ALL risk in the COG sample, with a
similar direction and magnitude of effect (OR = 1.15, 95% CI:
1.02–1.31, P = 0.025).
SNP imputation enabled improved resolution of the associated
regions in discovery samples (Fig. 2a–c). The SP4 association
peak is confined to the SP4 gene only (Fig. 2a) and conditional
analyses adjusting for rs2390536 revealed no independent risk
alleles (Supplementary Figure 1). Because rs2390536 did not
replicate in our combined replication set of CCLS Latinos and
COG Europeans, it may be a false-positive signal in our discovery
GWAS and therefore is not explored further here.
The chromosome 8q24 association peak was located within a
2.5 Mb region dense with genome-wide significant loci for a
variety of developmental traits, including: cleft lip14, hypospa-
dias15, and infant length16, as well as several cancers17. However,
our ALL association peak was located within a 100 kb subregion
(Fig. 2b), which has not been previously associated with any other
phenotype. Conditional analyses adjusting for the lead SNP in the
region greatly attenuated SNP associations in the region
(Supplementary Figure 2), with the most significant residual
association signal found at rs35380634, located some 300 kb
telomerically (Pconditional = 3.29 × 10−5).
The ALL association peak on chromosome 17q12 is broad,
covering approximately 200 kb and encompassing at least six
genes, including IKZF3 (Fig. 2c). The lead SNP, rs2290400, is
also a known GWAS hit for type 1 diabetes and asthma18,19,
although the ALL risk allele is protective against development
of these other immune-related phenotypes. Conditional
analyses adjusting for rs2290400 effectively eliminated any
residual association in the region, indicating that additional
risk loci proximal to the primary peak likely do not exist
(Supplementary Figure 3). Because IKZF1 also contains ALL
risk alleles identified in previous GWAS, we tested for the
presence of statistical interaction between our top genotyped
SNP in IKZF1 (rs11978267; PCCRLP = 2.15 × 10−29) and our top
genotyped SNP in IKZF3. We detected no significant epistatic
effect in either case–control analyses (P = 0.62) or case-only
analyses (P = 0.16).
Our study is designed to discover SNPs associated with case
status rather than the clinical course of disease. Within the COG
replication dataset, information on patient relapse was available
for all 959 cases, allowing for an assessment of risk of relapse. One
hundred forty-three patients experienced a relapse, while 816 did
not. Logistic regression analyses among these cases did not
suggest that either the rs4617118 risk allele on 8q24.1, nor the
rs2290400 risk allele near IKZF3, was associated with an increased
risk of relapse (OR = 1.03 and OR = 0.89; P = 0.87 and P = 0.39,
respectively).
Functional assessments. Top hit SNPs in the 8q24 and IKZF3
region, along with those that displayed larger effect sizes and P
values within one order of magnitude, were annotated for func-
tional evidence using HaploReg, RegulomeDB, and GTEx (Sup-
plementary Tables 4 and 5). ENCODE-described motifs that bind
at SNP locations, RegulomeDB scores, and other GWAS asso-
ciations are indicated in the tables. Additional expression quan-
titative trait loci (eQTL) analysis was carried out using RNA
sequencing (RNA-seq) data from lymphoblastoid cell lines
(LCLs) in the gEUVADIS dataset (www.geuvadis.org).
8q24: The risk locus at 8q24 is located within a gene desert and
is most proximal to, but outside of, a noncoding RNA LINC00977
(Fig. 3). The lead SNP, rs4617118, and those SNPs in tight linkage
were not eQTL for any proximal or distal gene in any tissue in
GTEx, nor for lymphoblastoid cells in gEUVADIS data. Many
GWAS association peaks for other cancers and immune
conditions exist on chromosome 8q24. Using chromatin
conformation assays on LCLs20, the region exhibits two large
structural chromosomal domains withMYC in the center (Fig. 3).
SNP rs4617118 exists within one of these domains. This domain
shows evidence of chromosome looping between MYC and the
region containing rs4617118; this region also contains the gene
GSDMC, on the distal side of rs4617118 (Fig. 3). GSDMC is a
gasdermin family member, another of which (GSDMB) is also
present within the chromosome 17q12 peak as explained below.
17q12: The genetic association peak at 17q12 was broad. The
top SNP rs2290400 is a highly significant eQTL (P values< 10−9)
for two genes, GSDMB and ORMDL3, in whole blood (as found
on gTEX, Fig. 4). An additional eQTL was identified at ZPBP2 in
the LCL RNA-seq data (−log10(P value) of 5.737). Structural Hi-C
Table 1 Lead SNPs near SP4, 8q24, and IKZF3 reaching genome-wide significance in discovery analyses of CCRLP acute
lymphoblastic leukemia patients, including replication analyses in the Children’s Oncology Group and the California Childhood
Leukemia Study Latino Participants
SP4—rs2390536 risk allele Aa 8q24.1—rs4617118 risk allele Gb IKZF3—rs2290400 risk allele Tc
RAFd P value OR (95% CI) RAFa P value OR (95% CI) RAFa P value OR (95% CI)
CCRLP meta-analysise 3.59 × 10−8 1.20 (1.13–1.29) 3.05 × 10−9 1.27 (1.17–1.38) 2.05 × 10−8 1.18 (1.11–1.25)
CCRLP Latinos 0.26 1.42 × 10−4 1.19 (1.09–1.31) 0.15 2.90 × 10−5 1.25 (1.12–1.38) 0.57 4.33 × 10−6 1.20 (1.11–1.30)
CCRLP Whites 0.35 5.69 × 10−5 1.23 (1.11–1.35) 0.18 1.74 × 10−3 1.26 (1.09–1.45) 0.50 2.72 × 10−3 1.15 (1.05–1.26)
CCRLP African Americans 0.22 0.73 1.07 (0.73–1.58) 0.23 1.55 × 10−3 1.54 (1.18–2.01) 0.52 0.18 1.19 (0.92–1.53)
Replication meta-analysis 0.075 1.10 (0.99–1.23) 1.29 × 10−4 1.30 (1.14–1.49) 0.013 1.14 (1.03–1.26)
COG Replication (European) 0.36 0.025 1.15 (1.018–1.31) 0.17 0.011 1.22 (1.05–1.43) 0.45 0.13 1.10 (0.97–1.25)
CCLS Replication (Hispanic) 0.2133 0.74 0.96 (0.77–1.20) 0.1069 1.03 × 10−3 1.58 (1.20–2.07) 0.6135 0.030 1.22 (1.02–1.46)
Combined datasets 1.77 × 10−8 1.18 (1.11–1.24) 1.76 × 10−12 1.28 (1.19–1.37) 1.06 × 10−9 1.17 (1.11–1.23)
RAF risk allele frequency, CCLS California Childhood Leukemia Study, CCRLP California Cancer Records Linkage Project, COG Children’s Oncology Group.
Bold values indicate P values lower than genome-wide significance (Po5 × 10−8) for CCRLP GWAS and combined datasets, and nominal significance (Po0.05) for replication meta-analysis.
a Rs2390536 was genotyped “on array” for all sample sets apart from COG Replication (Imputed INFO score= 0.99)
b rs4617118 was genotyped “on array for CCRLP datasets, and imputed for COG Replication (INFO= 0.96) and CCLS Replication (INFO= 0.88)
c rs2290400 was genotyped “on array” for all sample sets apart from COG replication (INFO= 0.88)
d RAF calculated among ethnicity-matched controls
e Sample sizes for all analyses: CCRLP Latinos: 1949 cases, 8584 controls; CCRLP whites: 1184 cases, 3551 controls; CCRLP African Americans: 130 cases, 3842 controls. For the replication: COG: 959
cases, 2624 controls; CCLS: 530 cases and 511 controls
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analysis (using LCL data) did not reveal obvious structural
interactions. The variant did not display any evidence of altering
expression of IKZF3 using gTEX or gEUVADIS resources, though
the linkage peak clearly covers this gene. Instead, the
rs2290400 minor allele, protective against ALL, was clearly
associated with decreased expression of its other associated gene
targets GSDMB and ORMDL3. Further analysis revealed that
rs2290400 disrupts a PRDM1 (BLIMP1) binding motif (Supple-
mentary Table S4).
Discussion
Using a population-based case-series with both matched controls
and additional controls from the same source population (albeit
older in age) and two replication datasets, we identified and
replicated two new genome-wide significant risk alleles for
childhood ALL. These alleles augment our current understanding
of the genetic etiology of childhood ALL by (i) adding one hap-
lotype that is a strong eQTL for three genes and located at a well-
established hematopoietic developmental gene (IKZF3), and (ii)
adding an additional locus in a gene-poor region of chromosome
8q24 that is rich with genetic variants affecting risk for myriad
different traits. A third association that reached genome-wide
significance in our discovery set (at the gene SP4) did not repli-
cate in the combined COG and CCLS replication data (P = 0.075).
Although it is not a confirmed risk factor for childhood ALL, it
did reach an overall P value below the commonly accepted
genome-wide significance level of 5 × 10−8 in our meta-analysis
and should be assessed in additional datasets.
While the associated haplotype on 17q12 clearly contains
IKZF3, the lead SNP rs2290400 was not identified as an eQTL for
IKZF3 itself using available databases. Instead, these databases
identified the neighboring genes ORMDL3, GSDMB, and ZPBP2
as top eQTLs. It is possible that the haplotype imparts more than
a single genic effect on risk. Prior GWAS have shown that the
ALL risk allele in rs2290400 (T) is protective against asthma19
and type 1 diabetes18, suggesting a role for this SNP in immune
regulation. An immunologic response role for the 17q12 haplo-
type is further supported by its association with a variety of other
conditions of aberrant immune function, including: primary
biliary cirrhosis21, systemic lupus erythematosus22, Crohn’s dis-
ease23, and ulcerative colitis24.
It is intriguing that the well-characterized ALL risk allele in
IKZF1 (Ikaros) is also protective against type 1 diabetes25, par-
alleling our findings at rs2290400 near IKZF3. The seeming
paradox wherein a risk allele for asthma and diabetes is associated
with decreased risk of childhood ALL, a disease also linked to
immune activation (as exemplified by an association with docu-
mented history of infectious diseases)26,27, may be explained by
complex interactions. While medical diagnosis of infection is
associated with an increased risk of childhood ALL, exposure to
infectious agents via daycare contact is associated with decreased
risk28. However, it is important to note that IKZF3, ZPB2,
ORMDL3, GSDMB, and GSDMA are structured in a large hap-
lotype with co-regulatory features29,30. The fact that IKZF3
encodes the TF Aiolos, closely related to another ALL-associated
TF Ikaros (IKZF1) that is also critical in hematopoietic devel-
opment and cell fate, and that IKZF3 has been identified as a
recurrent somatic deletion in leukemia31, suggests that it may be
the functional target of our GWAS association here. In support of
a causal role for rs2290400, this variant disrupts a binding motif
for the B lymphocyte maturation-induced protein 1 (BLIMP1), a
TF and known repressor of T-cell activation32. It is important to
note that BLIMP1 is expressed in early stages of B-cell
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Fig. 2 Genetic association peaks at chromosomes a 7, b 8, and c 17.
Genotypes include both “on array” SNPs and additional SNPs imputed as
described in the Methods. The top associated “on array” SNP from the
CCRLP/Kaiser discovery analysis is indicated by its “rs” identity (and purple
diamond shape), and other SNPs are displayed by color showing their
extent of genetic linkage with this top SNP. Recombination rate, genetic
position, and the locations of nearby genes are indicated. The P values for
the association at chromosome 7p15.3 (rs2390536, near SP4, OR= 1.20,
95% CI: 1.13–1.29, P= 3.6 × 10−8), chromosome 8q24.21 (rs4617118, OR=
1.27, 95% CI: 1.17–1.38, P= 3.1 × 10−9), and chromosome 17q12
(rs2290400, OR= 1.18, 95% CI: 1.11–1.25, P= 2.1 × 10−8)
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development32, and the SNP may affect risk via aberrant
expression control of IKZF3 at critical hematopoietic differ-
entiation junctures, similar to the activities of other SNPs known
to affect B-cell leukemia risk10. If the ALL risk allele at rs2290400
favored B-cell differentiation while the alternate allele favored T-
cell differentiation, this could potentially account for the inverse
association with ALL vs. asthma and type 1 diabetes. We cannot
at this point ascertain whether the 17q12 locus exerts functional
effects via its impact on hematopoietic differentiation or immune
response or both, and hence further research will be required.
The risk locus at 8q24, centered on rs4617118, is a unique
GWAS hit in a region rich with genetic associations. It is located
210,000 bases downstream of rs987525, a GWAS SNP for cleft
palate14, and over 400,000 bases upstream of a cluster of SNPs
associated with hypospadias, glioma, and white blood cell counts
(GWAS catalog). The 8q24 SNP associated with white blood cell
counts (rs1991866) is located near GSDMC. A related gene on
chromosome 17 (GSDMB) is found within the leukemia-
associated haplotype block containing IKZF3. These genes are
part of a family of genes involved in pyroptosis, or inflammatory
programmed necrosis, which is a recently identified pathway
involved in cell proliferation and differentiation, inflammatory
remodeling, and cancer-related pathways33. Whether any rela-
tionship exists between the 8q24 locus and these pathways is
unknown. Our preliminary suggestions on function of this allele
center around a putative impact on MYC regulation, in concert
with many other SNPs within the gene desert surrounding both
sides of MYC which appear to disrupt long-range enhancer
activity34, but do not exclude a potential effect on the function of
GSDMC, which is harbored within the same looping domain.
Limitations of the current study include a lack of precise
immunophenotype and tumor genetic information in our
discovery population. Also, the use of imputed SNPs for some
replication analyses as noted in Table 1 may introduce error,
although we note that the information scores of our top hit SNPs
were high. In addition, our initial goal was to discover aspects of
the genetic etiology that explained the higher rate of childhood
ALL in Latinos compared to non-Latino whites and the two new
loci discovered here do not appreciably account for differences in
genetic risk between these populations. Strengths of our discovery
population include a population-based sampling strategy for both
cases and controls that was not prone to participation bias, and
the close match between cases and controls in terms of birth date,
sex, and race/ethnicity are evidence for the lack of bias. Our
results suggest that genetic risk factors of reasonable strength may
continue to be discovered in population-based samples of child-
hood ALL.
Methods
Study subjects. The study protocol was approved by the Institutional Review
Boards at the California Health and Human Services Agency, University of Cali-
fornia (San Francisco and Berkeley), and Yale University. The California Depart-
ment of Public Health, Genetic Diseases Screening Branch obtains blood samples
(heel-prick blood spots) from all neonates born within the state for the purpose of
genetic screening. The blood spots that remain after genetic screening have been
archived at −20 °C since 1982 and made available for appropriate research. We
linked statewide birth records maintained by the California Department of Public
Health (for the years of 1982–2009) to cancer diagnosis data from the California
Cancer Registry (CCR, for the years of 1988–2011). Beginning in January 1988,
California law has required all new cancer cases diagnosed in state residents to be
reported to the CCR. Included in this analysis were children born in California
during 1982–2009 and diagnosed with ALL at the age of 0–14 years per CCR
record. Children who were born in California during the same period and not
reported to CCR as having any childhood cancer were considered potential con-
trols. For each case of childhood ALL, up to four control subjects were randomly
selected from the pool of potential controls and matched to the case on year and
month of birth, sex, and race/ethnicity (non-Latino white, non-Latino black,
Latino, Asian/Pacific Islander, other). This database of cancer cases and controls is
defined as the California Cancer Records Linkage Project (CCRLP). For the current
GWAS, a newborn blood spot was pulled from the archive for each case, as well as
one control randomly chosen from up to four matched controls for that case.
Therefore, active genotyping for CCRLP specifically for this project involved an
approximately equal number of cases and controls (see Supplementary Table 1).
CCRLP sample preparation and genotyping. DNA was extracted from neonatal
blood spots according to the Qiagen DNA Investigator blood card extraction
protocol. Three 3 mm punches (Wallac Multipuncher) were cut for each subject
and subjected to automated DNA extraction (Qiacube). DNA specimens were
assigned randomly to genotyping plates (93 unique samples per plate) and checked
for randomization to ensure that case–control status, ethnicity, and sex were dis-
tributed evenly. DNA was genotyped on the Affymetrix Axiom World Array
(Latino, or LAT) (plates 1–51, 60% of subjects) array35 and the same array sup-
plemented with MHC and KIR content for immunogenomic imputation pur-
poses36 on remaining samples (plates 52–86, 40% of subjects). The current
manuscript contains analyses of array content common to both array designs,
totaling 813,036 variants (i.e., the LAT array base content), plus an additional 8951
variants typed exclusively on plates 52–86. DNA samples were genotyped on an
Affymetrix TITAN system, and raw image files were processed with Affymetrix
Genetools to call genotypes. Plates 1–51 were clustered separately from plates 52 to
86 due to the differing SNP content, and then called genotypes were merged.
Genome freeze hg19 (NCBI 37) was used throughout as the reference.
CCRLP genotyping quality control. In addition to randomizing samples, we
included two duplicate samples per plate (174 total), with average genotype con-
cordance >99%. SNP filtering was performed separately for the two array designs
(i.e., plates 1–51 underwent SNP filtering separately from plates 52 to 86. Call-rate
filtering for SNPs and samples were performed iteratively, as follows: SNPs with
call rates <92% were removed, then samples with call rates <95% were excluded,
then SNPs with call rates <97% were removed, then samples with call rates <96%
were excluded. Additionally, 15 CEPH trios (parents and child) were genotyped to
detect and exclude SNPs showing >2 Mendelian transmission errors. Any SNP that
failed a quality control check on plates 1–51 was also excluded from analysis of
plates 52–86, and vice versa. Within the merged dataset of all CCRLP cases and
controls, we excluded any SNP displaying significant departure from
Hardy–Weinberg equilibrium (P< 1.0 × 10−4) among European-ancestry controls.
In addition to excluding samples due to call-rate filters (N = 167), samples with
mismatched reported vs. genotyped sex were also excluded (N = 26). We performed
identity-by-descent analyses in Plink on the merged dataset of all CCRLP cases and
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controls, stratified by ethnicity, and excluded one member of any sample pair that
had an identity-by-decent (IBD) proportion >0.20 (N = 13)37. We incorporated
genome-wide SNP array data from 1184 HapMap Phase 3 samples and performed
multidimensional scaling analysis using unlinked autosomal biallelic SNPs with
MAF> 0.05 allowing us to group 89.4% of cases and controls into one of three
analytic groups: Latinos, non-Latino whites, and African Americans.
Using hybridization intensity (log R ratio) data from array SNPs on
chromosome 21, we identified 109 subjects with Trisomy 21 (~2.9% of total cases)
and excluded these subjects from association tests due to the known differences in
leukemogenesis in diploid vs. constitutively aneuploid patients38. Three additional
cases were excluded because, on further examination, it was determined that ALL
was not their primary cancer diagnosis.
Incorporation of additional public controls. Axiom genotyping data for a total of
73,298 non-Latino white, Latino, and African-American subjects from the Kaiser
Resource for Genetic Epidemiology Research on Aging (GERA) Cohort were
downloaded from dbGaP (Study Accession: phs000788.v1.p2). All GERA partici-
pants are members of Kaiser Northern California Health Care, similar to the
CCRLP population. We restricted analyses to only those samples prepared using
the Axiom “Type O” Reagent Kit (N = 12,641), as this was the same kit used for
CCRLP samples. We excluded any SNPs that were not retained in the cleaned
CCRLP dataset, any SNP with an MAF <5%, any SNP associated with control
source (CCRLP vs. GERA) at P< 5 × 10−8 in race/ethnicity-stratified analyses, and
any SNP displaying significant departure from Hardy–Weinberg equilibrium (P<
1.0 × 10−4) among European-ancestry controls. Samples with call rates <97% were
also removed from analyses. The GERA control subject data were then merged
with the CCRLP dataset and IBD analyses were performed in Plink, excluding one
member of any sample pair that had an IBD proportion >0.20 (N = 161).
Discovery association analyses. Following SNP filtering procedures, a total of
757,935 polymorphic autosomal SNPs remained for analyses. Following sample
filtering procedures, a total of 3263 cases (1822 males, 1441 females) and 15,977
controls (7704 males, 8273 females) of Latino, non-Latino white, or African-
American ethnicity remained for analyses. This included a total of 3506 CCRLP
controls and 12,471 GERA controls. Case–control association tests were stratified
by ethnicity and included 10533 Latino subjects (1949 cases, 8584 controls), 4735
non-Latino white subjects (1184 cases, 3551 controls), and 3972 African-American
subjects (130 cases, 3842 controls). SNP associations were calculated using logistic
regression, adjusted for the first 10 ancestry-informative principal components
generated by Eigenstrat. Single SNP association results were computed assuming an
allelic additive model for 0, 1, or 2 copies of the minor allele. Genomic inflation
factors were calculated for each ethnicity-stratified GWAS and suggested
no substantial inflation of test statistics (λLatinos = 1.034; λnon-Latino whites = 1.004;
λAfrican Americans = 1.000) following adjustment for the first 10 principal compo-
nents. The ethnicity-stratified GWAS were subsequently combined using fixed-
effects meta-analysis, performed using Plink. SNPs achieving a P value <5.0 × 10−8
in the meta-analysis were considered to have achieved genome-wide statistical
significance by current convention and were carried forward for replication
analyses39.
Replication datasets. For replication, we used two additional sets of cases and
controls. The first is comprised of European-ancestry ALL patients from the COG
protocols 9904 and 9905 and controls from the Wellcome Trust Case–Control
Consortium. Constitutive DNA from COG samples was extracted from remission
blood40. DNA samples were genotyped on the Affymetrix 6.0 array and genotype
data were downloaded from dbGaP accession phs000638.v1.p1. Genotype data for
European-ancestry control samples genotyped on the Affymetrix 6.0 array were
downloaded from the Wellcome Trust Case–Control Consortium41. Genotyping
quality control procedures were conducted independently in cases and in controls9.
Briefly, samples with genotyping call rates <98% in cases or controls were exclu-
ded. SNPs with genotyping call rates <98% were excluded. We excluded subjects
showing evidence of non-European ancestry, samples with mismatched reported
vs. genotyped sex, and cryptically related subjects (IBD proportion >0.20), and
duplicated subjects already included in our discovery set (N = 21). COG and
WTCCC genotype data were merged to create a final set of 959 European-ancestry
ALL cases and 2624 controls.
A second replication set consisted of 530 Latino ALL cases and 511 Latino
controls from the CCLS that did not overlap with either the CCRLP discovery
dataset or the COG replication set. Pre-diagnostic constitutive DNA for CCLS
samples was extracted from neonatal bloodcards and genotyped using the Illumina
Human OmniExpress V1 platform. DNA extraction was performed using the
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA). Samples with genotyping
call rates <95% were excluded. Samples were screened for cryptic relatedness using
unlinked SNPs and excluded if IBD proportion >0.20. Samples with discordant sex
information (reported vs. genotyped sex) were excluded. SNPs with genotyping call
rates <95% were excluded. Any SNP with a Hardy–Weinberg equilibrium (HWE)
P value <1 × 10−4 in controls was excluded.
The COG ALL GWAS dataset were obtained from dbGaP study accession
phs000638.v1.p1 (Genome-Wide Association Study of Relapse of Childhood Acute
Lymphoblastic Leukemia). The ALL Relapse GWAS dataset was generated at St.
Jude Children’s Research Hospital and by the COG, supported by NIH grants
CA142665, CA21765, CA158568, CA156449, CA36401, CA98543, CA114766,
CA140729, and U01GM92666, Jeffrey Pride Foundation, the National Childhood
Cancer Foundation, and by ALSAC.
Replication association analyses and meta-analysis. Imputation was per-
formed for 1 Mb regions centered on three novel lead SNPs from the discovery
meta-analysis. Imputation was performed using the Impute2 v2.1.2 software
and its standard Markov chain Monte Carlo algorithm and default settings for
targeted imputation42. All 1000 Genomes Phase 3 haplotypes were provided as
the imputation reference panel43. SNPs with imputation quality (info) scores
<0.60 or posterior probabilities <0.90 were excluded to remove poorly imputed
SNPs. Association statistics for imputed and directly genotyped SNPs were
calculated using logistic regression in SNPTESTv2, using an allelic additive
model and probabilistic genotype dosages44. The effect of individual SNPs on
ALL risk was calculated while adjusting for principal components from
Eigenstrat.
Association statistics for the COG and CCLS replication datasets were
combined using fixed-effects meta-analysis in the META software package to
generate a summary odds ratio and P value for the combined replication dataset45.
The three novel lead SNP associations from discovery analyses were considered to
have been successfully replicated if they were statistically significantly associated
with ALL risk in this meta-analysis of replication datasets. To preserve the type I
error rate, replication P values rejection thresholds were adjusted for multiple
comparisons using the Bonferroni–Holm procedure.
A summary meta-analysis of all ALL cases and controls was calculated by
combining results from the three ethnicity-stratified discovery samples with the
COG and CCLS replication datasets using fixed-effects meta-analysis using the
META software45. As a measure for between-study heterogeneity, I2 was
calculated46.
Allelic functional characterization. Top hit SNPs were associated with genome-
wide gene expression using two datasets: the Genotype-Tissue Expression (GTEx)
O
RM
DL
3 
ex
pr
es
si
on
G
SD
M
B 
ex
pr
es
si
on
rs2290400 rs2290400
0.2
0.1
0.0
–0.1
0.2
0.1
0.0
–0.1
–0.2 –0.2
Homo Alt
N = 80
Het
N = 174
Homo Ref
N = 84
Homo Alt
N = 80
Het
N = 174
Homo Ref
N = 84
Fig. 4 GTEX expression quantitative trait analysis of rs2290400 (chromosome 17, reference allele T, alternative allele C). Data from whole blood samples
are shown, the significance of the eQTL was lower than a P value of 10−25 for both genes. Box plots depict the interquartile range, and error bars indicate 1.5
times the interquartile range
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02596-9
6 NATURE COMMUNICATIONS |  (2018) 9:286 |DOI: 10.1038/s41467-017-02596-9 |www.nature.com/naturecommunications
Project GTEx (Version 6p) on whole blood (n = 338) and LCLs (n = 114)47, and
gEUVADIS RNA sequencing project48. The GTEx Project data were obtained from
the GTEx Portal on 2 June 2017 and consist of data from dbGAP accession number
phs000424. gEUVADIS data is a database of RNA-Seq data derived from 423 LCLs
and their accompanying genotype data derived from low-pass whole-genome
sequencing as a part of 1000 Genomes project. SNP regions were also assessed with
Hi-Seq and Chia-PET chromosomal structure using Juicebox and data from
lymphoblastoid cell lines only49. Online databases, namely RegulomeDB50 and
Haploreg51, were utilized to glean functional information on SNPs.
Data availability. This study used biospecimens from the California Biobank
Program. Any uploading of genomic data and/or sharing of these biospecimens or
individual data derived from these biospecimens has been determined to violate the
statutory scheme of the California Health and Safety Code Sections 124980(j),
124991(b), (g), (h), and 103850 (a) and (d), which protect the confidential nature of
biospecimens and individual data derived from biospecimens. Certain aggregate
results may be available from the authors by request.
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